Here is what you need to know on Tuesday, October 6:
Risk-appetite led the way this Monday after a tense weekend with the news feeds flooded with Trump’s health-related headlines. Ahead of Wall Street’s close, the US President announced he would be leaving hospital later in the day, as he feels “20 years younger.” Trump received a series of experimental drugs, and of course, had an army of doctors taking care of him. Meanwhile, the number of new contagions among White House staff skyrocketed.
Hopes that the US Congress would clinch a deal on the next round of fiscal stimulus also underpinned the market’s sentiment. Treasury Secretary Mnuchin and House Speaker Pelosi were reported to have a phone call to discuss the matter. They will continue negotiating this Tuesday.
Market players were also confident that the UK and the EU might agree on a post-Brexit trade deal after authorities from both sides agreed to extend negotiations until month-end. This Monday, they start a two-week round of talks, aimed to find some common ground on fisheries rights and a level playing field, the two most relevant issues.
The EUR/USD pair flirted with 1.1800 while GBP/USD neared 1.3000, as European currencies were the best performers against the greenback. The pairs pulled back a bit ahead of the close but held to most of their intraday gains.
The Canadian dollar posted a modest intraday advance, helped by rising crude oil prices. The Aussie, however, remained within familiar levels, ahead of the RBA’s monetary policy decision.
Wall Street closed with substantial gains, with the S&P reaching its highest in almost a month.
Gold surged amid a weaker greenback, and hopes of more stimulus coming from the US. The bright metal settled above $1,910 a troy ounce, its highest settlement in over two weeks. Crude oil prices recovered on the back of rallying equities, trimming Friday’s losses. WTI ended at $39.30 a barrel.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.